Who wins the obesity-drug race may hinge on deal architecture, not just data. We unpack Pfizer’s challenge to Novo Nordisk’s Metsera bid—focusing on a 30-month outside date, restrictive covenants and an unusual cash structure—and what it means for investors and founders navigating GLP-1.
Read the full analysis: https://biotech.industryexaminer.com/the-obesity-wars-go-to-court-pfizer-says-novos-metsera-bid-is-a-moat-not-a-merger/

#GLP1 #Biotech #MergersAndAcquisitions #Antitrust #PharmaStrategy #TechNews